ClinicalTrials.gg
CompletedNCT07943429Updated Nov 17, 2026

Strategies to Improve RTS,S-4 Uptake and Integration With Other Child Health Services

An interventional study of Provide ITNs at RTS,S-4 visit and Community Health Promoters identify and refer under-vaccinated children to health facilities in Malaria Vaccine, sponsored by Kenya Medical Research Institute. Completed at 1 site in Kenya. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Kenya Medical Research Institute · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2025, registered Oct 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 95 studies in Malaria with a site in Kenya — 7 open to participants now, 10 under way, 2 of them phase 3. Malaria · Kenya.

Enrollment
22nd of 81
2,346 · median 600
Started
2025
with 3 others
No phase
27 of 95
4 open now
Registered
95th of 95
by date

Among the 95 studies in Malaria with a site in Kenya, this one is the 22nd largest by enrollment of the 81 interventional ones that give a count, is one of 4 that started in 2025, is one of 27 with no phase, and was the 95th registered.

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

7 of the 95 studies in Malaria with a site in Kenya are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Kenya have not opened yet or have stopped. Only those recruiting at a site in Kenya →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Malaria with a site in Kenya, or all of them as a file.
02

Study summary

This study will identify and evaluate innovative approaches to leverage malaria vaccine visits as opportunities to enhance the delivery of other child health services in Rarieda sub-county, Siaya County, Kenya where RTS,S became part of their routine childhood immunization programs in 2019. Using a human-centred design approach, the implementation research will be conducted in two phases.

Phase 1 (Diagnose and Design) will consist of formative research to understand current practices, barriers, and facilitators for childhood health and malaria interventions using the WHO's behavioural and social drivers' framework for immunization. Having identified the barriers and facilitators to uptake, the investigators will prioritize drivers and develop innovations for implementation in collaboration with communities, healthcare workers and managers.

Phase 2 (Implement and Evaluate) will focus on implementing and evaluating the innovations developed in Phase 1. Using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) Framework, the study will assess the extent to which the interventions reach the target population, effectiveness of leveraging the malaria vaccine to increase uptake of other child health interventions, the extent of adoption by key stakeholders, and the fidelity and quality of implementation. The investigators will also explore cost and long-term sustainability.

The study will employ a mixed-methods approach, leveraging quantitative and qualitative data from health facility records, surveys, interviews, and observations.

The investigators will generate evidence on leveraging malaria vaccine visits and activities through: (i) innovative implementation strategies designed to maximize immunizations, child health interventions, and malaria prevention uptake; (ii) community engagement as an approach to optimize vaccine uptake and coverage; (iii) detailed qualitative data on the acceptability, perceptions, and barriers to uptake of vaccines and child health interventions; (iv) approaches to ensure access for zero-dose, under-vaccinated and underserved populations.

03

Conditions studied

  • Malaria Vaccine

Browse trials for

Keywords

  • malaria
  • malaria vaccine
  • RTS,S/AS01
  • RTS,S-4
  • Immunization
  • Implementation science
  • Feasibility
  • Community health
  • Human-centred design
  • BeSD framework
  • RE-AIM framework
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. Primary caregivers of children eligible for malaria vaccination:

    • Inclusion criteria: Primary caregivers (age 18 years or older) of children who are eligible for or have received at least one dose of malaria vaccine
    • Exclusion criteria: Caregivers who are not the primary decision-makers for the child's healthcare or who have resided in the study area for less than 3 months
  2. Healthcare workers involved in immunization services:

    • Inclusion criteria: Clinical officers, nurses, or other healthcare staff directly involved in providing immunization services at the selected health facilities for at least 3 months
    • Exclusion criteria: Healthcare workers not involved in immunization service delivery or who have worked at the facility for less than 3 months
  3. Community health promoters (CHPs):

    • Inclusion criteria: CHPs working in the catchment areas of selected health facilities for at least 6 months
    • Exclusion criteria: CHPs who have not been active in the past 3 months
  4. Community members and leaders:

    • Inclusion criteria: community members and leaders willing to share their views on malaria vaccine barriers and facilitators, and approaches to improve uptake.
    • Exclusion criteria: Community members not willing to participate in the study
  5. Health facility managers and sub-county/county/national health officials:

    • Inclusion criteria: Health facility in-charges, sub-county or county EPI coordinators, and other relevant health officials overseeing immunization services across MoH hierarchy
    • Exclusion criteria: Officials who have been in their current position for less than 3 months
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,346 participants (actual)

Study arms

  • Experimental
    ITN - Provision of ITNs at RTS,S-4 visit

    Leverage malaria vaccine to improve ITN access and use by providing ITNs at the 4th malaria dose visit, as well as vitamin A, deworming, MR2 and other missing vaccines

    Behavioral: Provide ITNs at RTS,S-4 visit

  • Experimental
    CHP - CHP identify and refer under-vaccinated children to health facility

    Using malaria vaccine as an entry point, CHPs systematically identified under-vaccinated children during routine household visits and referred them to health facilities (HF), integrating immunization tracking into routine community activities.

    Behavioral: Community Health Promoters identify and refer under-vaccinated children to health facilities

  • Experimental
    SMS - Enhanced defaulter tracing with use of mobile technology

    Facility-community linkages were strengthened through CHP engagement and mobile phone-based reminders, including SMS notifications and defaulter tracing

    Behavioral: Enhanced defaulter tracing with use of mobile technology

  • Experimental
    SS - Strengthening immunization systems, health services, and interdepartmental collaboration

    Multi-component intervention: 1) strengthening immunizations and health services through interdepartmental collaboration; 2) improving vaccine visit awareness, preparedness, and defaulter tracing; and 3) targeted monthly community outreaches, with CHPs mobilizing caregivers of children due or overdue for vaccination.

    Behavioral: Strengthening immunization systems, health services, and interdepartmental collaboration

Interventions

  • BehavioralProvide ITNs at RTS,S-4 visit

    \- At RTS,S-4 visit, health workers (HW) screen children for missing vaccinations and health services - HW provide catch-up vaccinations and services

  • BehavioralCommunity Health Promoters identify and refer under-vaccinated children to health facilities

    * CHP screen households for under-vaccinated children * CHP Provide referral for immunization * HW vaccinate referred children * HW provide catch-up vaccinations and services * CHP follow up on referral completion

  • BehavioralEnhanced defaulter tracing with use of mobile technology

    * HF diaries to record expected children on each date * HW record phone contacts in diaries to remind caregivers about visits (SMS or calls) * If caregivers cannot be reached, HW share contacts by SMS/WhatsApp with CHPs to trace defaulters at the house and provide referrals * HW screen \& provide catch-up vaccinations \& services

  • BehavioralStrengthening immunization systems, health services, and interdepartmental collaboration

    * Screening children for vaccination status at triage * HW use colored ink to better visualize return dates in home-based records * HW Screen \& provide catch-up vaccinations \& services * CHPs trace defaulters, provide \& follow up on referrals * HF diaries to record expected children on each date * HF conduct targeted community outreaches * CHP mobilize defaulters for scheduled outreaches

06

What researchers measure

Primary outcomes

  1. Reach

    Vaccine coverage (%) in target populations and characteristics of vaccinated populations reached through study interventions

    Time frame: Three months

  2. Effectiveness

    Percentage increase in primary (dose 1-3) and booster (4th) doses post-interventions in age-eligible children

    Time frame: Three months

  3. Adoption

    Proportion of RTS,S vaccines provided concurrently with other vaccines/services.

    Time frame: Three months

  4. Implementation

    Perceived feasibility of interventions by health workers, caregivers, and community. A semi-structured interview guide will be used to assess implementation experiences.

    Time frame: Three months

  5. Maintenance

    Drivers of maintenance of interventions. A semi-structured interview guide will be used to elicit what it would take to continue implementing interventions beyond the study period.

    Time frame: Three months

07

Study locations

1 site
  • Ong'ielo Health Centre
    Siaya, Kenya
08

References and documents

Publications

  • UNICEF Office of Innovation. Human-Centered Design. UNICEF.
  • Malaria vaccines (RTS,S and R21). WHO. https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine.
  • Kenya Medical Research Institute, Centers for Disease Control and Prevention. Kenya MVPE Feasibility Evaluation: Results of the baseline household survey. Published November 2020.
  • President's Malaria Initiative. Kenya PMI Fact Sheet In-Country FY 2023. PMI.gov. https://www.pmi.gov/wp-content/uploads/2023/04/Kenya_PMI-Fact-Sheet-InCountry_FY2023_CP_checked.pdf
  • Boselli G, Yajima A, Aratchige PE, Feldon KE, Xeuatvongsa A, Phounphenghak K, Sihakhang K, Chitsavang C, Phengkeo S, Gabrielli AF, Politi C, Montresor A. Integration of deworming into an existing immunisation and vitamin A supplementation campaign is a highly effective approach to maximise health benefits with minimal cost in Lao PDR. Int Health. 2011 Dec;3(4):240-5. doi: 10.1016/j.inhe.2011.08.002. PubMed 24038496 ↗
  • Wallace A, Dietz V, Cairns KL. Integration of immunization services with other health interventions in the developing world: what works and why? Systematic literature review. Trop Med Int Health. 2009 Jan;14(1):11-9. doi: 10.1111/j.1365-3156.2008.02196.x. Epub 2008 Nov 12. PubMed 19017307 ↗
  • Ching P, Birmingham M, Goodman T, Sutter R, Loevinsohn B. Childhood mortality impact and costs of integrating vitamin A supplementation into immunization campaigns. Am J Public Health. 2000 Oct;90(10):1526-9. doi: 10.2105/ajph.90.10.1526. PubMed 11029982 ↗
  • Oresanya O, Phillips A, Okereke E, Ahmadu A, Ibinaiye T, Marasciulo M, Ward C, Adesoro O, Mohammed R, Nikau J, Isokpunwu CO, Inname MA, Counihan H, Baker K, Maxwell K, Smith H. Co-implementing vitamin A supplementation with seasonal malaria chemoprevention in Sokoto State, Nigeria: a feasibility and acceptability study. BMC Health Serv Res. 2022 Jul 5;22(1):871. doi: 10.1186/s12913-022-08264-z. PubMed 35791014 ↗
  • National Malaria Control Programme. Towards Malaria-Free Kenya: Kenya Malaria Strategy 2019-2023. Nairobi, Kenya: Ministry of Health; 2019.
  • Elnour Z, Grethe H, Siddig K, Munga S. Malaria control and elimination in Kenya: economy-wide benefits and regional disparities. Malar J. 2023 Apr 7;22(1):117. doi: 10.1186/s12936-023-04505-6. PubMed 37029370 ↗

Individual participant data

Plan to share: No — Only aggregated data is required for reports and manuscripts.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 5 months is below that.

Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Nov 17, 2026
StartActual
Jul 1, 2025
Primary completionActual
Dec 4, 2025
CompletionActual
Dec 4, 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943429
Lead sponsor
Kenya Medical Research Institute
Collaborators
Liverpool School of Tropical Medicine, Centers for Disease Control and Prevention
Responsible party
Simon Kariuki (Senior Principal Research Scientist, Kenya Medical Research Institute) — Principal investigator
First posted
Nov 17, 2026
Start date
Jul 1, 2025
Primary completion
Dec 4, 2025
Completion
Dec 4, 2025
Last update
Nov 17, 2026

Study contacts

Simon Kariuki, PhD
principal investigator · Kenya Medical Research Institute
Nelli Westercamp, PhD
principal investigator · Centres for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion